Compare Church & Dwight Co., Inc. (CHD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Revvity Inc — how do they compare? Church & Dwight Co., Inc. trades at $101.39 (market cap $24.38B), while Revvity Inc trades at $114.95 (market cap $12.91B). The key difference: Church & Dwight Co., Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| CHD | RVTY | |
|---|---|---|
Market Cap | $24.38B | $12.91B |
Sector | Consumer Staples | Technology |
52-Week High | $105.26 | $117.75 |
52-Week Low | $81.60 | $82.26 |
Enterprise Value | $26.38B | $15.23B |
Dividend Yield | 1.2% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $103.30, up 0.06% today, near its consensus price target of $103.57. The stock shows bullish technical signals with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, Q2 2026 earnings met estimates with 5.8% organic sales growth, and the company raised full-year guidance. Recent news highlights volume-driven performance and market share gains.
The outlook remains positive given raised earnings guidance and consistent dividend payments, but risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with 53% buy ratings, supporting a stable investment case for long-term growth in the consumer staples sector.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
